IRWD
IRONWOOD PHARMACEUTICALS INC
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$3.56
+1.71%Oct 16, 2026, 11:41 UTC
Ironwood Pharmaceuticals said Thomas McCourt will retire as chief executive officer and leave the board of directors, effective December 31, 2026.
Oct 16, 2026, 11:41 UTC
Ironwood Pharmaceuticals appointed Tammi Gaskins as chief executive officer and elected her to its board of directors, effective January 1, 2027; her annual base salary is $775,000, with a 75% target bonus and target equity grants valued at approximately $2 million each in RSUs and PSUs.
Aug 6, 2026, 20:04 UTC
Ironwood Pharmaceuticals started enrollment in its confirmatory Phase III study of apraglutide.
Source:Aug 6, 2026, 00:00 UTC
Ironwood Pharmaceuticals reported Q2 2026 total revenue of $113 million, GAAP net income of $51 million, and adjusted EBITDA of $83 million, with LINZESS US net sales of $282 million for the quarter.
Aug 6, 2026, 00:00 UTC
Ironwood Pharmaceuticals repaid $200 million principal of its convertible notes.
Source: